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ABSTRACT 
Simple, accurate, precise, and sensitive ultraviolet spectrophotometric and reversed-phase high-performance liquid chromatographic 
(RP-HPLC) methods for simultaneous estimation of Atorvastatin (ATOR) and Pioglitazone (PIO) in combined tablet dosage form 
have been developed and validated. The spectroscopic methods employs formation and solving of simultaneous equation at 247 nm 
and 267 nm as 2 wavelengths for estimation of ATOR and PIO respectively (method 1) While method 2 involves formation of Q- 
absorbance equation at 233 nm (isoabsorptive point) and 267 nm (λ max of Pioglitazone) with methanol as solvent. Beer’s law is 
obeyed in the concentration range of 5.0–50.0 mcg/mL for ATOR and PIO, respectively. The RP-HPLC method uses HPLC system 
with a Phenomenex Luna C18 (5 m x 25cm x 4.6mm i.d) using Methanol, acetonitrile and potassium dihydrogen phosphate buffer, 
pH 2.5 adjusted with orthophosphoric acid (60:20:20 v/v) at a flow rate of 1.0 mL/min at ambient temperature as the mobile phase. 
The detection was carried out using an ultraviolet detector set at 233 nm. For the HPLC method, Beer’s law is obeyed in the 
concentration range of 5.0-50.0 µg/ml for ATOR and PIO, respectively. LOD values for ATOR and PIO were found to be 
57.12µg/ml and 12.01 µg /ml respectively. All the methods have been successfully applied for the analysis of the drugs in a 
pharmaceutical formulation. Results of analysis were validated statistically and by recovery studies.1-4 
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INTRODUCTION: 
Atorvastatin[R-(R,R)]-2-(4-fluorophenyl)-ß,δ-
dihydroxy-5-(1-methylethyl)-3-phenyl-4 [(phenylamino) 
carbonyl] -1H-pyrrole 1-heptanoic acid is a 
hypolipidemic agent which is used for treatment of 
hyperlipidemia and Pioglitazone (±)-5-[[4-[2-(5-ethyl-2-
pyridinyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione 
monohydrochloride is a hypoglycemic agent which is 
used in treatment of hyperglecemia. 
A literature survey revealed that different analytical 
methods involving Specrtrophotometric and column 
high-performance liquid chromatography (HPLC) for 
determination of ATOR and PIO in biological fluids and 
in pharmaceutical preparations have been developed. 
Because of absence of an official pharmacopoeial 
method for the simultaneous determination of ATOR 
and PIO in pharmaceutical formulations, efforts were 
made to develop an analytical method for estimation of 
ATOR and PIO in their combined dosage form using 
HPLC method and UV Spectroscopy. 
MATERIALS AND METHODS: 
Instruments 
 A UV-visible (UV-Vis) double beam 
spectrophotometer (Model 1601; shimadzu) with 1 cm 
matched quartz cells was used for the 
spectrophotometric method. For the HPLC method, an 
HPLC system consisting of pump (Shimadzu LC 10AT 
VP ) with universal loop injector (Rheodyne 7725 i) of 
injection capacity 20  L. Detector consists of 
photodiode array detector (PDA) SPD-10 AVP UV-
Visible detector, for separation column used was 
Phenomenex Luna C18 (5 m x 25cm x 4.6mm i.d).  
Method I: Simultaneous equation method. 
This spectrophotometric technique is employed when 
the two absorbing drugs in the sample X and Y absorbs 
at the λ max of each other. The standard solution of 
strength 100 µg/ml of ATOR and PIO were prepared in 
methanol separately. From overlain spectra of ATOR 
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(10 µg/ml) and PIO (10 µg/ml) two wavelengths 247nm 
(λ max of ATOR) and 267 nm (λ max of PIO) were 
selected for the formation of simultaneous equation. 
Different aliquots were taken from stock solutions and 
diluted with the same solvent to prepare a series of 
concentrations. The calibration curves were found to be 
linear in concentration range of 5-50 µg/ml for ATOR 
and PIO respectively. The absorbance of ATOR and 
PIO were measured at 247nm and 267nm which are 
respective Wavelength of both the drugs respectively. 
The concentration of two drugs in mixture can be 
calculated by using simultaneous equation. 
Method II: Q-absorbance method 
Q-absorbance method uses the ratio of Absorbances at 
two selected wavelength,one at isoabsorptive point and 
other being the λmax of one of the two components. The 
standard solution of strength 100mcg/mL of ATOR and 
PIO were prepared in methanol separately. From 
overlain spectra of ATOR (10 µg/ml) and PIO (10 
µg/ml) two wavelengths 233nm (Isoabsorbtive point) 
and 267 nm (λ max of PIO) were selected for the 
formation of Q-absorbance equation. Different aliquots 
were taken from stock solutions and diluted with the 
same solvent to prepare a series of concentrations. The 
calibration curves were found to be linear in 
concentration range of 5-50 µg/ml for ATOR and PIO 
respectively. The absorbance of ATOR and PIO were 
measured at 233nm and 267nm. 
Method III: HPLC 
Method Validation  
(a) Linearity.-Calibration graph was constructed 
by plotting peak area vs. Concentration of ATOR and 
PIO and the regression equations were calculated. The 
calibration graph were plotted over 5 different 
concentrations (10, 20,30,40,50 µg/ml) using methanol. 
Aliquots (20µL) of each solution were injected under 
the chromatographic conditions. 
(b) Accuracy- The accuracy of the methods was 
determined by calculating recoveries of ATOR and PIO 
by standard addition method. Known amounts of mixed 
standard solution of ATOR and PIO   (80,100 and 
120%) were added to prequantitated sample solutions of 
tablet dosage form. The amount of ATOR and PIO were 
estimated by applying values of peak area to the 
regression equation of the calibration graph. 
(c) Method precision (repeatability) - The 
precision of the instrument was checked by repeatedly 
injecting (n=6) mixed standard of ATOR and PIO 
(20µg/ml). 
(d) Intermediate precision (reproducibility) - 
The intraday and interday precision of proposed 
methods were determined by analyzing mixed standard 
solution of ATOR and PIO at 3 different concentrations, 
and three times on the same day and on three different 
days. The results are    reported in the terms of Relative 
standard deviation.(RSD) 
(e) Limit of detection (LOD) and limit of 
quantitation LOQ: The LOD with signal-to-noise ratio 
of 3:1 and with S/N ratio of 10:1 were calculated for 
both the drugs using the following equations 
LOD=3.3*σ/s                      LOQ=10* σ/s 
RESULTS AND DISCUSSION:  
The proposed method was found to be simple, accurate, 
economical, and rapid for routine analysis of ATOR and 
PIO in combined dosage form. The accuracy of method 
was determined by calculating the mean percentage 
recovery. Precision was determined as inter and intraday 
variation for both the drugs. Both methods were 
successfully used to estimate the amount of ATOR and 
PIO present in marketed formulation. For the RP-HPLC 
method, chromatographic conditions were optimized to 
achieve the best resolution and peak shape for ATOR 
and PIO. Different mobile phases containing methanol, 
Acetonitrile and 0.05 M Potassium Di hydrogen 
phosphate were examined (data not shown), and the 
mobile phase methanol, acetonitrile–0.05 M Potassium 
di hydrogen phosphate, pH adjusted to 2.5 ±0.1 (60 
:20:20, v/v/v) was selected as optimal for obtaining 
Well-defined and resolved peaks. The optimum 
wavelength for detection and quantitation was 233 nm, 
at which the best detector response for both the 
substances was obtained Straight line calibration curves 
were obtained for ATOR and PIO in the 
spectrophotometric and RP-HPLC methods. The 
proposed methods were also evaluated in the assay of 
commercially available tablets containing ATOR and 
PIO. Six replicate determinations were performed on the 
accurately weighed amounts of tablets. For ATOR, 
recovery (mean, %, ± SD, n = 6) was found to be 99.48 
± 1.10, 100.05±0.613 and 100.16 ± 0.616 for Methods 
I,II and III, respectively. For PIO, recovery was found to 
be 99.89 ± 0.15, 100.10±0.56 and 99.30 ± 0.35 for 
Methods I, II and III, respectively. For ATOR, the 
recovery study results ranged from 99.34 to 100.1%, 
99.98 %to 100.02% and 100.1 %to 100.94 %for 
Methods I, II and III, respectively. For PIO, the recovery 
results ranged from 99.92 %to 99.75%, 99.27% to 
99.23% and 100.30% to 100.33% for Methods I, II and 
III, 
CONCLUSION:  
The results confirmed that the method is simple, precise 
and accurate. The method can be used for the routine 
simultaneous analysis of ATOR and PIO in 
pharmaceutical preparations. 
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